NASDAQ:ETNB 89bio (ETNB) Stock Price, News & Analysis → Everybody laughed when he recommended Netflix (From Stansberry Research) (Ad) Free ETNB Stock Alerts $8.95 +0.01 (+0.11%) (As of 05/21/2024 ET) Add Compare Share Share Today's Range$8.72▼$9.0550-Day Range$8.25▼$13.5252-Week Range$6.57▼$22.93Volume418,456 shsAverage Volume1.12 million shsMarket Capitalization$880.50 millionP/E RatioN/ADividend YieldN/APrice Target$28.14 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get 89bio alerts: Email Address 89bio MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.71 Rating ScoreUpside/Downside214.4% Upside$28.14 Price TargetShort InterestBearish10.93% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.04Based on 20 Articles This WeekInsider TradingAcquiring Shares$20.72 M Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($2.32) to ($3.06) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.22 out of 5 starsMedical Sector542nd out of 921 stocksPharmaceutical Preparations Industry244th out of 413 stocks 4.4 Analyst's Opinion Consensus Rating89bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst Coverage89bio has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about 89bio's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted10.93% of the outstanding shares of 89bio have been sold short.Short Interest Ratio / Days to Cover89bio has a short interest ratio ("days to cover") of 9.4.Change versus previous monthShort interest in 89bio has recently decreased by 4.10%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend Yield89bio does not currently pay a dividend.Dividend Growth89bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ETNB. Previous Next 1.6 News and Social Media Coverage News Sentiment89bio has a news sentiment score of -0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 20 news articles for 89bio this week, compared to 3 articles on an average week.Search InterestOnly 2 people have searched for ETNB on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows6 people have added 89bio to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, 89bio insiders have bought 42,916.84% more of their company's stock than they have sold. Specifically, they have bought $20,722,500.00 in company stock and sold $48,173.00 in company stock.Percentage Held by InsidersOnly 2.80% of the stock of 89bio is held by insiders.Read more about 89bio's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for 89bio are expected to decrease in the coming year, from ($2.32) to ($3.06) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of 89bio is -4.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of 89bio is -4.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share Ratio89bio has a P/B Ratio of 1.56. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about 89bio's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchEverybody laughed when he recommended Netflix"This Could be Worth Even More than A.I." Whitney Tilson's nailed many of the most famous stocks of the last 25 years – including Netflix, Amazon, and Apple. Now he's pounding the table on a new technology rolling out across America, which early estimates say could create more wealth than A.I., the personal computer, and the smartphone combined. Click here to see how it could become the No. 1 investment of the next decade. About 89bio Stock (NASDAQ:ETNB)89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.Read More ETNB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ETNB Stock News HeadlinesMay 21 at 4:22 AM | americanbankingnews.com89bio, Inc. (NASDAQ:ETNB) Receives Consensus Rating of "Moderate Buy" from AnalystsMay 20 at 4:48 AM | americanbankingnews.com89bio (NASDAQ:ETNB) Stock Rating Reaffirmed by HC WainwrightMay 20 at 2:16 AM | americanbankingnews.comFinancial Contrast: 89bio (NASDAQ:ETNB) vs. Eyenovia (NASDAQ:EYEN)May 19 at 5:04 AM | americanbankingnews.com89bio (NASDAQ:ETNB) Stock Rating Reaffirmed by Cantor FitzgeraldMay 17, 2024 | americanbankingnews.comEvercore ISI Lowers 89bio (NASDAQ:ETNB) Price Target to $33.00May 16, 2024 | markets.businessinsider.comBuy Rating for 89bio on Pegozafermin’s Promise in Advanced NASH TrialsMay 16, 2024 | americanbankingnews.comFY2024 Earnings Estimate for 89bio, Inc. (NASDAQ:ETNB) Issued By Cantor FitzgeraldMay 15, 2024 | morningstar.com89bio Inc Ordinary SharesMay 14, 2024 | markets.businessinsider.comOppenheimer Reaffirms Their Hold Rating on 89bio (ETNB)May 14, 2024 | globenewswire.com89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated CirrhosisMay 14, 2024 | americanbankingnews.com89bio (NASDAQ:ETNB) Price Target Lowered to $29.00 at HC WainwrightMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for 89bio Amid Pegozafermin’s Clinical Advances and Market PotentialMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for 89bio Amid Promising Drug Candidate Progress and Strategic ReadinessMay 10, 2024 | finance.yahoo.com89bio Inc (ETNB) Reports Increased Losses in Q1 2024 Despite Advancements in Clinical TrialsMay 10, 2024 | globenewswire.com89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 9, 2024 | msn.comETNB Stock Earnings: 89bio Misses EPS for Q1 2024May 9, 2024 | globenewswire.com89bio Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 8, 2024 | globenewswire.com89bio to Participate in the BofA Securities 2024 Health Care ConferenceMay 2, 2024 | finance.yahoo.com89bio to Host Key Opinion Leader Webinar on Pegozafermin’s Opportunity in Advanced MASHMay 2, 2024 | globenewswire.com89bio to Host Key Opinion Leader Webinar on Pegozafermin's Opportunity in Advanced MASHApril 24, 2024 | investing.comBofA raises 89bio to stock buy amid MASH outlookApril 22, 2024 | finance.yahoo.com89bio, Inc. (ETNB) Stock Historical Prices & Data - Yahoo FinanceApril 17, 2024 | globenewswire.com89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of DirectorsApril 5, 2024 | globenewswire.com89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 3, 2024 | finance.yahoo.com89bio Inc CEO Rohan Palekar Sells 52,718 SharesSee More Headlines Receive ETNB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 89bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today5/21/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ETNB CUSIPN/A CIK1785173 Webwww.89bio.com Phone415-432-9270FaxN/AEmployees70Year FoundedN/APrice Target and Rating Average Stock Price Target$28.14 High Stock Price Target$37.00 Low Stock Price Target$14.00 Potential Upside/Downside+215.5%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($2.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-142,190,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-34.76% Return on Assets-31.05% Debt Debt-to-Equity Ratio0.05 Current Ratio15.03 Quick Ratio15.03 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.75 per share Price / Book1.55Miscellaneous Outstanding Shares98,380,000Free Float95,629,000Market Cap$877.55 million OptionableOptionable Beta1.15 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Rohan Palekar (Age 58)CEO & Director Comp: $990.52kMr. Quoc Le-Nguyen (Age 56)Chief Technical Operations Officer & Head of Quality Comp: $654.44kDr. Harry Mansbach M.D. (Age 59)Chief Medical Officer Comp: $691.87kMr. Ryan Stephen Martins (Age 45)Chief Financial Officer Mr. Shiva K. Natarajan CPA (Age 58)Senior Vice President of Finance & Principal Accounting Officer Ms. Annie J. Chang M.B.A.VP of Investor Relations & Corporate CommunicationsMs. Amanda KuriharaVice President of People & CultureMs. Yun Bai Ph.D.VP and Head of Chemistry, Manufacturing & Controls ( CMC )Ms. Melissa AbelSenior Vice President of Commercial StrategyMr. Paul ShinSenior Vice President of R&D OperationsMore ExecutivesKey CompetitorsImmunomeNASDAQ:IMNMOPKO HealthNASDAQ:OPKCentessa PharmaceuticalsNASDAQ:CNTAAlbireo PharmaNASDAQ:ALBOABIVAX Société AnonymeNASDAQ:ABVXView All CompetitorsInsiders & InstitutionsRA Capital Management L.P.Bought 1,350,000 shares on 5/17/2024Ownership: 12.977%Comerica BankBought 15,070 shares on 5/17/2024Ownership: 0.174%Janus Henderson Group PLCBought 3,688,241 shares on 5/16/2024Ownership: 12.811%Redmile Group LLCBought 295,164 shares on 5/16/2024Ownership: 2.302%Bellevue Group AGSold 6,500 shares on 5/15/2024Ownership: 0.014%View All Insider TransactionsView All Institutional Transactions ETNB Stock Analysis - Frequently Asked Questions Should I buy or sell 89bio stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for 89bio in the last twelve months. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ETNB shares. View ETNB analyst ratings or view top-rated stocks. What is 89bio's stock price target for 2024? 7 analysts have issued twelve-month price targets for 89bio's shares. Their ETNB share price targets range from $14.00 to $37.00. On average, they anticipate the company's share price to reach $28.14 in the next twelve months. This suggests a possible upside of 214.4% from the stock's current price. View analysts price targets for ETNB or view top-rated stocks among Wall Street analysts. How have ETNB shares performed in 2024? 89bio's stock was trading at $11.17 at the beginning of 2024. Since then, ETNB shares have decreased by 19.9% and is now trading at $8.95. View the best growth stocks for 2024 here. When is 89bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024. View our ETNB earnings forecast. How were 89bio's earnings last quarter? 89bio, Inc. (NASDAQ:ETNB) posted its quarterly earnings data on Wednesday, May, 15th. The company reported ($0.54) earnings per share for the quarter, missing analysts' consensus estimates of ($0.46) by $0.08. During the same period last year, the firm posted ($0.54) earnings per share. What ETF holds 89bio's stock? AdvisorShares Dorsey Wright Micro-Cap ETF holds 2,900 shares of ETNB stock, representing 0.92% of its portfolio. What other stocks do shareholders of 89bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other 89bio investors own include Cisco Systems (CSCO), Pfizer (PFE), CVS Health (CVS), RTX (RTX), Alibaba Group (BABA), Procter & Gamble (PG), Sorrento Therapeutics (SRNE), Johnson & Johnson (JNJ) and Thermo Fisher Scientific (TMO). When did 89bio IPO? 89bio (ETNB) raised $70 million in an initial public offering (IPO) on the week of November 11th 2019. The company issued 4,400,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets acted as the underwriters for the IPO and Oppenheimer was co-manager. Who are 89bio's major shareholders? 89bio's stock is owned by a variety of institutional and retail investors. Top institutional investors include RA Capital Management L.P. (12.98%), Janus Henderson Group PLC (12.81%), Vanguard Group Inc. (4.96%), Redmile Group LLC (2.30%), Westfield Capital Management Co. LP (2.27%) and University of Wisconsin Foundation (0.51%). Insiders that own company stock include Edward Morrow Atkinson III, Kathleen Laporte, Michael R Hayden, Ollin B Sykes, Orbimed Advisors Llc, Quoc Le-Nguyen, Ra Capital Management, LP, Ram Waisbourd, Rohan Palekar and Ryan Martins. View institutional ownership trends. How do I buy shares of 89bio? Shares of ETNB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ETNB) was last updated on 5/21/2024 by MarketBeat.com Staff From Our PartnersShocking $16T Elon Musk Crypto LeakCrypto 101 MediaExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsNext President (Not Trump. Not Biden.)The Freeport SocietyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsWarren Buffett's "mystery stock"Stansberry ResearchThis Could be Your “Big Money” AI MomentInvestorPlaceWrite this ticker symbol down…StocksToTrade Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 89bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
